Vevo Therapeutics, a San Francisco, CA-based biotechnology company, raised $12M in Seed funding.
The round was led by Wing Venture Capital and General Catalyst with participation from Mubadala Capital, AIX Ventures, and Camford Capital.
The company intends to use the funds to accelerate growth and expand operations.
Led by Nima Alidoust, Ph.D., Chief Executive Officer and Co-founder, and Kevan Shokat, Ph.D., Co-founder, Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and AI models to uncover drugs for more patients. Its Mosaic platform makes in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to represent patient diversity in drug response over current in vitro assays.
The platform builds on technology developed by two of its co-founders, Hani Goodarzi, Ph.D., Associate Professor at the University of California, San Francisco (UCSF), and Johnny Yu, Ph.D., Chief Scientific Officer of Vevo Therapeutics. The company holds an exclusive license to the technology from UCSF’s Innovation Ventures office, which leads licensing and business development on behalf of the university.
FinSMEs
08/12/2022